Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.

Abstract

We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychotic features were controlled after both antipsychotics were discontinued and the patient was treated instead with olanzapine.

• Authors: Pang-Yen Liu, Pei-Chuan Wu, Chun-Yen Chen, Yi-Chyan Chen
• Journal: General hospital psychiatry (Gen Hosp Psychiatry) 2011 Jan-Feb Vol. 33 Issue 1 Pg. 84.e5-7 ISSN: 1873-7714 [Electronic] United States
• PMID: 21353143 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Crown Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antipsychotic Agents
• fluphenazine depot
• Risperidone
• Fluphenazine

Topics

• Adult
• Antipsychotic Agents (administration & dosage, adverse effects, therapeutic use)
• Delusions (drug therapy)
• Female
• Fluphenazine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Neuroleptic Malignant Syndrome (etiology)
• Risperidone (administration & dosage, adverse effects, therapeutic use)
• Schizophrenia, Paranoid (drug therapy)